glp 1 agonist gastroparesis GLP-1 Receptor Agonists in Gastrointestinal Practices: Enhancing Both Procedural and Patient-Related Outcomes | SN Comprehensive Clinical Medicine A 32-year-old man developed gastroparesis

GLP-1 receptor agonists, already used for Type 2 diabetes and obesity, show promise in reducing alcohol and drug-seeking behaviors through central reward and dopamine-related pathways

Approved 20 years ago as a treatment for diabetes, GLP-1 drugs have been found also to help patients significantly reduce weight

Why diabetes drugs are driving tech-like returns in healthcare.

Its cognitive-support properties have been extensively studied

Curious how they work?

Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a groundbreaking treatment for Type 2 diabetes mellitus (T2DM) and obesity